Br J Ophthalmol 2000;84:293-299
( March )
Effects of topical nipradilol, a
blocking agent with
blocking and nitroglycerin-like activities, on intraocular pressure and
aqueous dynamics in humans
Mikiko Kannoa, Makoto Araiea, Hiroshi Koibuchib, Kanjiro Masudaa
a Department
Opthalmology, University of Tokyo School of Medicine, Japan, b Section
of Ophthalmology, JR Tokyo General Hospital, Japan
Correspondence to: Makoto Araie, Department of Ophthalmology, University of Tokyo School
of Medicine, 7-3-1 Hongo, Bunkyou-ku, Tokyo 113, Japan
Accepted for publication 1 October 1999
AIMS
To study the
effects of topical nipradilol, a non-selective
blocker with
blocking and nitroglycerin-like activities, on intraocular pressure
(IOP) and aqueous humour dynamics in normal humans and in patients with
ocular hypertension.
METHODS
Nipradilol
(0.06%, 0.125%, 0.25%, 0.5%) was applied to normal volunteers (n = 12) to test for IOP lowering effects. In a second group of normal
volunteers (n = 11), nipradilol (0.125% and 0.25%) and timolol
(0.5%) were compared for IOP lowering effects. After a single
administration of 0.25% nipradilol, IOP, flare intensity in the
anterior chamber, aqueous flow, uveoscleral outflow, tonographic outflow facility, and episcleral venous pressure were either directly measured or mathematically calculated. Topical nipradilol (0.25%) was
administered to 24 patients with ocular hypertension twice daily for 8 weeks.
RESULTS
Administration
of 0.25% nipradilol decreased IOP with a maximum reduction of 4.2 mm
Hg lasting 12 hours. A single instillation of both 0.25% nipradilol
and 0.5% timolol reduced the IOP in normotensive human subjects to the
same degree. A single instillation of 0.25% nipradilol decreased the
aqueous flow rate in the treated eye by 20%. Nipradilol produced no
significant effect in tonographic outflow facility or episcleral venous
pressure, but uveoscleral outflow was increased. In patients with
ocular hypertension, twice daily instillation of 0.25% nipradilol
decreased IOP without tachyphylaxis for the 8 week test period.
CONCLUSION
Topical
nipradilol (0.25%) reduced IOP by decreasing the aqueous flow rate and
probably also by increasing uveoscleral outflow. Nipradilol should be
further investigated as a new antiglaucoma drug.
© 2000 by British Journal of Ophthalmology